Home > Haematology > EHA 2020 > Plasma Cell Dyscrasias > Isatuximab triplet improves PFS in R/R MM

Isatuximab triplet improves PFS in R/R MM

Presented By
Prof. Philippe Moreau, University Hospital of Nantes, France
EHA 2020
Phase 3, IKEMA
The triplet therapy of anti-CD38 isatuximab, carfilzomib, and dexamethasone gave a significant improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (R/R MM). Prof. Philippe Moreau (University Hospital of Nantes, France) presented the interim results of the open-label phase 3 IKEMA study [1]. This study randomised 302 patients with R/R MM who had previously received 1 to 3 lines of therapy to receive either intravenous isatuximab at 10 mg/kg plus carfilzomib and dexamethasone (n=179) or carfilzomib/dexamethasone alone (n=123). Isatuximab was administered weekly for 4 weeks, and then every 2 weeks. Carfilzomib was administered at 20 mg/m2 on the first 2 days and then 56 mg/m2 twice-weekly thereafter for 3 to 4 weeks, followed by twice-weekly dexamethasone ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on